The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

ABSTRACT: Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.

SUBMITTER: Goker Bagca B 

PROVIDER: S-EPMC7305753 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature